Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 06, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...
DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19
January 05, 2022 08:00 ET
|
Daxor Corporation
Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
January 04, 2022 08:00 ET
|
Daxor Corporation
Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
November 16, 2021 08:00 ET
|
Daxor Corporation
Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021 ...
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care
November 09, 2021 08:00 ET
|
Daxor Corporation
Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
October 01, 2021 08:30 ET
|
Daxor Corporation
The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:...
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
September 14, 2021 08:30 ET
|
Daxor Corporation
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...
Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021
September 08, 2021 08:30 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure...
Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 07, 2021 08:30 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
September 01, 2021 08:30 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter to...